Why testing immunogenicity of biologics?

Immunogenicity is the capacity to induce an immune response. Every protein-based molecule has an immunogenic potential.

While immunogenicity is seeked for vaccines, it is a serious issue for therapeutic proteins (such as antibodies, peptides, hormones, etc…).

Protéus, in collaboration with immunology experts at the CEA, has developed Immuno’line™, a range of technologies and services for early evaluation of immunogenicity in Human.

The CEA has gained its expertise through the design of vaccinating peptides or allergens for desensitisation, and the study of biologics. Protéus has leveraged this 10 years experience to build robust and high performance immunogenicity testing services.

Immuno’line™ services have been developed to bring you clear insights on the immunogenicity of your proteins and help your decisions.

Immuno'line™ services:

Through its exclusive partnership with the CEA (IBiTec), Protéus brings 10 years of experience and unique technologies to the market, with the aim of addressing the major issue of immunogenicity.

These technologies are available in the Immuno'line™ services:

T-cell activation assays
HLA binding assays
Immunogenicity engineering

Benefits of Immuno'line™:

For Biologics (where goal is to avoid immune response):

• Ranking of your protein candidates vs highly and low immunogenic control proteins.
• Engineering safer versions
• Comparison of formulations
• Benchmarking of biosimilars

For Vaccines (where goal is to induce immune response):

• Design of peptide vaccines
• Validation of subunit vaccines
• Development of tools for immunomonitoring

With Immuno'line™:

• Design improved versions of your biologics
• Increase the chances of success in clinical development
• Increase the value of your molecules